Plant ID: NPO6331
Plant Latin Name: Jacobaea subalpina
Taxonomy Genus: Jacobaea
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
189250
Plant-of-the-World-Online:
n.a.
GPR35; | |
NPSR1; | |
RECQL; TDP1; HPGD; HSD11B1; AKR1B10; ALOX12; AKR1B1; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
TEK; MET; INSR; AXL; SRC; FLT3; CDK1; EGFR; PIM1; NUAK1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA7; CA4; | |
RORC; | |
NR1H4; | |
KDM4E; | |
TYR; | |
AHR; | |
FUT7; | |
SLC22A6; | |
SMAD3; LMNA; APP; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 5.573E-11 | 7.138E-08 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, NR1H4, PIM1, SMAD3, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.765E-09 | 2.414E-06 | AKR1B1, AKR1B10, APP, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD17B2, NR1H4 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.189E-08 | 3.924E-06 | AKR1B1, AKR1B10, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD11B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.769E-08 | 1.140E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.731E-08 | 1.981E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.715E-08 | 2.497E-05 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.379E-07 | 3.481E-05 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.060E-07 | 6.940E-05 | AKR1B1, APEX1, CA2, CSNK2A1, CYP1A2, EGFR, FLT3, HPGD, INSR, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.297E-07 | 7.327E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.972E-07 | 1.905E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.051E-06 | 1.956E-04 | EGFR, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.499E-06 | 2.698E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.568E-06 | 2.798E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.702E-06 | 3.013E-04 | APP, EGFR, INSR, KDR, NOX4, SMAD3, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.563E-06 | 5.464E-04 | CA12, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.904E-06 | 5.904E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.002E-06 | 7.261E-04 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.548E-06 | 7.794E-04 | APEX1, POLB |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.547E-06 | 7.794E-04 | APP, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.956E-06 | 9.407E-04 | APP, EGFR, KDR, NOX4, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 8.783E-06 | 1.132E-03 | CDK1, EGFR, IGF1R, INSR |
MF | Unclassified; | GO:0004872; receptor activity | 9.285E-06 | 1.189E-03 | AHR, AXL, EGFR, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, RORC, TEK |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 9.488E-06 | 1.208E-03 | AKR1B1, APEX1, APP, IGF1R, INSR, SRC |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.164E-05 | 1.424E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.302E-05 | 1.567E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.404E-05 | 1.626E-03 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.631E-05 | 1.850E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.662E-05 | 1.865E-03 | CA2, CA7 |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.721E-05 | 1.920E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.823E-05 | 2.005E-03 | AKR1B1, APEX1, APP, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.165E-05 | 2.311E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.165E-05 | 2.311E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:1901992; positive regulation of mitotic cell cycle phase transition | 2.300E-05 | 2.433E-03 | APEX1, APP, CDK1, CYP1A1 |
BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 3.003E-05 | 3.036E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, PIM1 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.277E-05 | 3.212E-03 | CYP1A1, LMNA, NOX4, SMAD3, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.319E-05 | 3.212E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 3.319E-05 | 3.212E-03 | APP, INSR |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 3.647E-05 | 3.468E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 4.422E-05 | 4.029E-03 | AXL, IGF1R, INSR |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 4.767E-05 | 4.255E-03 | AXL, CYP1A1, CYP1A2, HPGD, NR1H4, SRC |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.906E-05 | 4.307E-03 | FLT3, SRC, TEK |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 5.476E-05 | 4.674E-03 | AHR, AXL, CSNK2A1, EGFR, RORC, SRC |
BP | GO:0009987; cellular process | GO:1902905; positive regulation of supramolecular fiber organization | 5.538E-05 | 4.674E-03 | APP, HSPA1A, MET, NOX4, SMAD3 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.849E-05 | 4.918E-03 | AHR, NR1H4, PIM1, RORC, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.973E-05 | 4.983E-03 | AHR, CSNK2A1, KDR |
BP | Unclassified; | GO:1990535; neuron projection maintenance | 8.272E-05 | 6.474E-03 | APP, INSR |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 8.272E-05 | 6.474E-03 | ALOX12, HPGD |
BP | GO:0008152; metabolic process | GO:0016101; diterpenoid metabolic process | 8.295E-05 | 6.474E-03 | AKR1B10, CYP1A1, CYP1B1, EGFR |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 8.633E-05 | 6.642E-03 | APP, CDK1, EGFR, SMAD3 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 9.019E-05 | 6.891E-03 | APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, PIM1, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 9.757E-05 | 7.301E-03 | HSPA1A, MET, NOX4, SMAD3, TEK |
MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 1.088E-04 | 8.029E-03 | CYP1A1, CYP1A2, KDM4E |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.094E-04 | 8.049E-03 | AHR, APP, EGFR, IGF1R, INSR, SMAD3 |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.156E-04 | 8.365E-03 | EGFR, POLB |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.156E-04 | 8.365E-03 | FLT3, KDR |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.265E-04 | 8.912E-03 | EGFR, INSR, SMAD3 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.321E-04 | 9.279E-03 | CA2, CA7, KDR, NPSR1, SRC |
BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 1.383E-04 | 9.623E-03 | APP, CA2, CA7, GPR35, NOX4, NPSR1, NR1H4, SMAD3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.386E-10 | 4.266E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.009E-07 | 4.238E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.972E-07 | 1.253E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.152E-07 | 6.780E-06 | HSD11B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.959E-06 | 4.114E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.701E-08 | 3.592E-06 | CA12, CA2, CA4, CA7 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.283E-05 | 2.309E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.373E-05 | 3.738E-04 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.002E-04 | 1.027E-03 | SRC, KDR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.239E-04 | 1.115E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 9.793E-05 | 1.027E-03 | SRC, KDR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.167E-05 | 1.027E-03 | INSR, TEK, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.757E-05 | 5.259E-04 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.214E-04 | 3.187E-03 | HSD11B1, FUT7, AKR1B10, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALOX12, TYR, HSD17B10 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.456E-04 | 2.063E-03 | SMAD3, INSR, EGFR, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.060E-04 | 1.027E-03 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 4.300E-04 | 3.187E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.921E-04 | 3.408E-03 | FLT3, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 5.139E-04 | 3.408E-03 | SRC, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.833E-04 | 3.675E-03 | MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.709E-04 | 4.626E-03 | HPGD, FLT3, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.530E-03 | 8.035E-03 | SRC, EGFR, HSPA1A |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.090E-03 | 6.241E-03 | SRC, CDK1, EGFR |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.270E-03 | 6.955E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
NA: NA | HIV infections | NA | AHR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; INSR; AKR1B1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; APP; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; TEK; EGFR; SRC; APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
NA: NA | Geographic retinal atrophy | NA | APP; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |